EP0150235A1 - Dérivés de 3-pyrrolidinopropiophénone et procédé pour leur préparation - Google Patents

Dérivés de 3-pyrrolidinopropiophénone et procédé pour leur préparation Download PDF

Info

Publication number
EP0150235A1
EP0150235A1 EP84100827A EP84100827A EP0150235A1 EP 0150235 A1 EP0150235 A1 EP 0150235A1 EP 84100827 A EP84100827 A EP 84100827A EP 84100827 A EP84100827 A EP 84100827A EP 0150235 A1 EP0150235 A1 EP 0150235A1
Authority
EP
European Patent Office
Prior art keywords
formula
pyrrolidinopropiophenone
compounds
acid
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP84100827A
Other languages
German (de)
English (en)
Other versions
EP0150235B1 (fr
Inventor
Yasuo Itho
Hideo Kato
Nobuo Ogawa
Eiichi Koshinaka
Hiroyuki Nishino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Japan Co Ltd
Original Assignee
Hokuriku Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HU33131D priority Critical patent/HU33131A/hu
Priority to US06/573,862 priority patent/US4638009A/en
Application filed by Hokuriku Pharmaceutical Co Ltd filed Critical Hokuriku Pharmaceutical Co Ltd
Priority to EP84100827A priority patent/EP0150235B1/fr
Priority to DE8484100827T priority patent/DE3466689D1/de
Priority to FR8402469A priority patent/FR2559771B1/fr
Publication of EP0150235A1 publication Critical patent/EP0150235A1/fr
Application granted granted Critical
Publication of EP0150235B1 publication Critical patent/EP0150235B1/fr
Expired legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Definitions

  • This invention relates to novel derivatives of 3-pyrrolidinopropiophenone and the pharmaceutically acceptable acid addition salts thereof, which exibit a potent activity on muscle relaxation and to/a process for preparation thereof.
  • this invention relates to the derivatives of 3-pyrrolidinopropiophenone represented by formula(I) : wherein R represents an ethyl-, propyl-, isopropyl-, butyl-and isobutylgroup or a cycloalkylgroup having 5-7 carbon atoms and the pharmaceutically acceptable acid addition salts thereof, as well as to a process for preparation thereof.
  • Tolperisone (generic name, Merck Index, 9th Edition, 9219) represented by formula(II) : was on the market and been widely provided for clinical usage of the treatment of muscular contractive and spastic paralysis.
  • Eperisone (WHO Chronicle, 36 (2), Proposed International Nonproprietary Names : List 47) represented by formula(III) : has been prepared and already clinically used.
  • Eperisone of formula(III) shows an improvement in muscle relaxation activity.
  • Eperisone dose not show an improvement in toxicity and has just the same strong toxicity as Tolperison.
  • Eperison causes the hepatic and kidneys functional disorder, while Tolperisone possesses only the hepatic functional disorder. Therefore, Eperisone is rather regressive than Tolperisone in respect to the unwanted side effects.
  • examples of cycloalkyl- group shown by R are a cyclopentyl-, cyclohexyl- and cycloheptylgroup.
  • the compounds represented by formula(I) can be converted into the corresponding pharmaceutically acceptable acid addition salts in a conventional.manner and the base can be liberated from the so prepared acid addition salts, if necessary.
  • Examples of the pharmaceutically acceptable acid addition salts of the compounds represented by formula(I), are salts with a mineral acid, such as hydrochloric acid, nitric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, phosphoric acid and the like, and with an organic acid, such as acetic acid, maleic acid, fumaric acid, citric acid, oxalic acid, tartaric acid and the like.
  • a mineral acid such as hydrochloric acid, nitric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, phosphoric acid and the like
  • an organic acid such as acetic acid, maleic acid, fumaric acid, citric acid, oxalic acid, tartaric acid and the like.
  • the novel derivative of 3-pyrrolidinopropiophenone represented by formula(I) can be prepared by reacting a derivative of propiophenone represented by formula(IV) : wherein R is as defined above, with a formaldehyde and pyrrolidine represented by formula(V): or the salt thereof in a solvent.
  • a formaldehyde to be used for the preparation formaldehyde, linear or cyclic polymer of formaldehyde, such as paraformaldehyde, trioxane and the like, can be considered.
  • Pyrrolidine is used usually as a salt of a mineral acid such as hydrochloric acid, hydrobromic acid and nitric acid, whereas the pyrrolidine in the form of base is reacted in acid reaction medium by adding the sufficient amount of a mineral acid to the reaction mixure.
  • a mineral acid such as hydrochloric acid, hydrobromic acid and nitric acid
  • the mole ratio of the reactants can be chosen freely. However, 1 mol of pyrrolidine represented by formula(V) is reacted with at least 1 mol, preferably 1.1 moles of a derivative of propiophenone represented by formula(IV) and at least 1 mol, preferably 1.5 moles of formaldehyde, so that the pyrrolidine used can be eliminated from the reaction mixture, which should be submited to an after treatment.
  • Solvent used in the process of this invention is an alcoholic solvent such as methanol, ethanol, propanol, isopropanol and the like, a nitroalkanic solvent, such as nitromethane, nitroethane and the like, a lower alkyl ester of lower aliphatic acid, such as methyl acetate, ethyl acetate, ethyl propionate and the like.
  • a lower alkyl ester of a lower aliphatic acid such as methyl acetate, ethyl acetate, ethyl propionate and the like.
  • the lower alkyl ester of a lower aliphatic acid Preferably can be used the lower alkyl ester of a lower aliphatic acid.
  • the reaction can be carried out at a temperature between room temperature and the boiling point of a solvent used, preferably at the boiling point of the solvent.
  • the compounds of this invention exhibit strong muscle relaxant activity with minimized side effects.
  • the high order of these activities of the active agent of this invention is evidenced by test in lower animals, representative of which are reported herein.
  • the compound of this invention can be administered per os, e. g., in the form of pills or tablets, in which it may be-present together with the usual pharmaceutical carriers, conventionally by compounding the compounds of this invention together with a customary carrier or adjuvant, such as talc, magnesium stearate, starch, lactose, gelatin, any of numerous gums, and the like.
  • a non-toxic pharmaceutical carrier in addition to the active ingredient of this invention.
  • Exemplary solid carriers are lactose, magnesium stearate, calcium stearate, starch, terra alba, dicalcium acacia, or the like.
  • liquid carriers are peanut oil, sesame oil, olive oil, water, or the like.
  • the active agents of this invention can be conveniently administered in such compositions containing active ingredient so as to eventually be within the dosage range illustrated hereafter.
  • a wide variety of pharmaceutical forms suitable for many modes of adminstration and dosages may be employed.
  • the active ingredient and pharmaceutical forms suitable for many modes of administration and dosages may be employed.
  • the active ingredient and pharmaceutical carrier may, for example, take the form of a granule, pill, -tablet, lozenge, elixir, syrup,or other liquid suspension or emulsion, whereas, for parenteral administration, the composition may be in the form of a sterile solution or suppository.
  • the method of using the compounds of this invention comprises internally or externally administering the compounds of this invention, preferably orally or parenterally and preferably admixed with the pharmaceutical carrier, for example, in the form of any of the above compositions, or filled into a capsule, to alleviate conditions to be treated and symptoms thereof in a living animal body.
  • the pharmaceutical carrier for example, in the form of any of the above compositions, or filled into a capsule.
  • it may be used in an amount of about 1 to about 100 mg. per unit dose, preferably 30 to 80 mg. for an oral dose, while parenteral dosages are usually less and ordinarily about one-half of the oral dose.
  • the unit dose is preferably given a suitable number of times daily, typically three times. The daily dose may vary depending upon the number of times given.
  • Fig.l The effective activity on muscle relaxation (rotating rod test), nicotine-induced convulsion and oxotremorine-induced tremor is shown in Fig.l, Table 1 and 2 respectively as one example representing the potentiating pharmacological effect of the inventive compounds.
  • the mice were tested previously by using rotating rod of 3cm in diameter at the rate of 10r.p.m. and the mice which can stay on the rotating rod during more than 60 seconds were selected for the test.
  • the compounds were administrated per os at a dose of 200 mg/kg and after 10, 20, 30 and 60 minutes of drug administration the mice were moved on the rotating rod. The times (seconds) of staying on the rod have been measured. It has been judged as the compound is efffective, if the mice have failed from the rod before 60 sec. staying. The results are shown in the Figure 1.
  • mice Male ddY mice 5 weeks old were used as 5 animals at a group. The compounds were administrated per os at a dose of 25 mg/kg. After 15 minutes of drug administration, Nicotin tartarate has been administrated intraveniously at a amount of 3mg/kg .and the tonic convulsion'and dead animals because of the convulsion have been measured. The effect of the compounds has been indicated by percentage of appearance of tonic convulsion and the mortality.
  • LD 50 was determined by the Probit method from dead animals within 7 days.
  • the acute toxicity test shows that the compounds of the invention have a lower LD 50 value as compared with Eperisone. Therefore, it is clear that the compounds of the invention are very useful as a medicine for clinical usage because of the superior pharmacological effects and of the lower toxicity.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP84100827A 1984-01-26 1984-01-26 Dérivés de 3-pyrrolidinopropiophénone et procédé pour leur préparation Expired EP0150235B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
HU33131D HU33131A (fr) 1984-01-26
US06/573,862 US4638009A (en) 1984-01-26 1984-01-25 Derivatives of 3-pyrrolidinopropiophenone and a process for preparation thereof
EP84100827A EP0150235B1 (fr) 1984-01-26 1984-01-26 Dérivés de 3-pyrrolidinopropiophénone et procédé pour leur préparation
DE8484100827T DE3466689D1 (en) 1984-01-26 1984-01-26 Derivatives of 3-pyrrolidinopropiophenone and a process for preparation thereof
FR8402469A FR2559771B1 (fr) 1984-01-26 1984-02-17 Derives de la 3-pyrrolidinopropiophenone et procede pour leur preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP84100827A EP0150235B1 (fr) 1984-01-26 1984-01-26 Dérivés de 3-pyrrolidinopropiophénone et procédé pour leur préparation

Publications (2)

Publication Number Publication Date
EP0150235A1 true EP0150235A1 (fr) 1985-08-07
EP0150235B1 EP0150235B1 (fr) 1987-10-07

Family

ID=8191722

Family Applications (1)

Application Number Title Priority Date Filing Date
EP84100827A Expired EP0150235B1 (fr) 1984-01-26 1984-01-26 Dérivés de 3-pyrrolidinopropiophénone et procédé pour leur préparation

Country Status (5)

Country Link
US (1) US4638009A (fr)
EP (1) EP0150235B1 (fr)
DE (1) DE3466689D1 (fr)
FR (1) FR2559771B1 (fr)
HU (1) HU33131A (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295411A1 (fr) * 1987-05-15 1988-12-21 Sansho Co., Ltd. Préparation pharmaceutique pour l'administration percutanée contenant de l'épérisone ou tolpérisone ou l'un de leurs sels
EP0423524A2 (fr) * 1989-09-28 1991-04-24 MARUHO Co., Ltd. Dérivés de propiophénone et leur préparation et application pharmaceutique

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0637389B2 (ja) * 1986-12-26 1994-05-18 北陸製薬株式会社 頻尿治療剤
DE10123129A1 (de) * 2001-05-02 2002-11-14 Berolina Drug Dev Ab Svedala Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel
CA2651732C (fr) * 2006-05-18 2014-10-14 Mannkind Corporation Inhibiteurs de kinases intracellulaires
CN102015606B (zh) 2007-06-08 2015-02-04 满康德股份有限公司 IRE-1α抑制剂
KR101462468B1 (ko) 2012-11-26 2014-11-18 주식회사 엔지켐생명과학 염산 에페리손의 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254341A1 (fr) * 1973-12-14 1975-07-11 Eisai Co Ltd
EP0004000A1 (fr) * 1978-02-22 1979-09-19 Nippon Zoki Pharmaceutical Co. Ltd. Dérivés de propanone, procédé pour leur préparation et compositions pharmaceutiques contenant ces dérivés comme éléments actifs
EP0040744A1 (fr) * 1980-05-22 1981-12-02 Bayer Ag Oximes d'aminopropiophénone, procédés pour leur préparation et leur application comme fongicides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3252996A (en) * 1962-10-02 1966-05-24 Ciba Geigy Corp Alpha-pyrrolidinomethyl valero and caprophenones
US3151124A (en) * 1961-11-20 1964-09-29 Ciba Geigy Corp Alpha oxy-beta alkyl-gamma tertiary amino-alpha phenyl propanes
US3995047A (en) * 1973-12-14 1976-11-30 Eisai Co., Ltd. Propiophenone derivatives in the treatment of pathological muscular conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254341A1 (fr) * 1973-12-14 1975-07-11 Eisai Co Ltd
EP0004000A1 (fr) * 1978-02-22 1979-09-19 Nippon Zoki Pharmaceutical Co. Ltd. Dérivés de propanone, procédé pour leur préparation et compositions pharmaceutiques contenant ces dérivés comme éléments actifs
EP0040744A1 (fr) * 1980-05-22 1981-12-02 Bayer Ag Oximes d'aminopropiophénone, procédés pour leur préparation et leur application comme fongicides

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295411A1 (fr) * 1987-05-15 1988-12-21 Sansho Co., Ltd. Préparation pharmaceutique pour l'administration percutanée contenant de l'épérisone ou tolpérisone ou l'un de leurs sels
EP0423524A2 (fr) * 1989-09-28 1991-04-24 MARUHO Co., Ltd. Dérivés de propiophénone et leur préparation et application pharmaceutique
EP0423524A3 (en) * 1989-09-28 1992-07-08 Maruho Co., Ltd. Propiophenone derivatives and their preparation and pharmaceutical use

Also Published As

Publication number Publication date
FR2559771B1 (fr) 1986-12-26
US4638009A (en) 1987-01-20
HU33131A (fr) 1984-10-29
EP0150235B1 (fr) 1987-10-07
DE3466689D1 (en) 1987-11-12
FR2559771A1 (fr) 1985-08-23

Similar Documents

Publication Publication Date Title
US4001238A (en) 1,3,4-oxadiazole amides
US3639477A (en) Novel propoxyguanidine compounds and means of producing the same
GB2243832A (en) 2-substituted 4-acetamido-5-chloro-n-[2-(diethylamino)ethyl]-benzamide derivative
US4983633A (en) Amide compounds, process for preparing the same, and composition for activating gastric motor function containing the same
EP0150235B1 (fr) Dérivés de 3-pyrrolidinopropiophénone et procédé pour leur préparation
NZ187763A (en) 3-aryloxy-1-(2-(indol-3-yl)-1,1-dimethylethyl)amino-propan-2-ols
US4636513A (en) Isoxazole derivatives and medicaments containing these compounds
HU181147B (en) Process for preparing substituted heterocyclin phenoxamines
US3459767A (en) Aminomethylindoles
US4105769A (en) Inhibition of indoleamine-N-methyl transferase by 2-iminopyridines
US4478838A (en) 1-(3,4,5-Trimethoxycinnamoyl)-4-alkylaminocarbonylethyl piperazines
US2918407A (en) Anti-spasmodics specific for upper gastrointestinal pain and spasm
EP0042366A1 (fr) Diphénylbutyl-1-acylpipérazines
CA1218374A (fr) Derives de la 3-pyrrolidinopropiophenone et preparation
SU862825A3 (ru) Способ получени 3- 4-(2 -пиридил)-пиперазин-1-ил -1-(3,4,5-триметоксибензоилокси)пропана или его дигидрохлорида
GB1580227A (en) Piperazine derivatives
KR900006096B1 (ko) 3-피롤리디노프로피오페논 유도체의 제조방법
US3973017A (en) Imidazothiazines, derivatives and analogues thereof
US3274248A (en) N-1, 1-bis-[aminophenyl]-propyl-amines and salts thereof
US3553267A (en) 3-dimethylamino-1,2,3,4-tetrahydrofluorene
US4259257A (en) 1-Phenyl-2-amino-1,3-propanediol-N-aryloxyalkyl derivatives
US3928341A (en) N-Aminoalkyl-4-anilino pyridines
US4199582A (en) Piperazine containing dihydronaphthalene derivatives and compositions
US4271161A (en) Indane-acetic acid aminoesters, their preparation and their use in therapy
JPH0680041B2 (ja) ２−ピリジル酢酸誘導体、その製法およびそれを含む医薬

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE CH DE GB IT LI NL SE

17P Request for examination filed

Effective date: 19860124

17Q First examination report despatched

Effective date: 19870225

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): BE CH DE GB IT LI NL SE

ITF It: translation for a ep patent filed

Owner name: STUDIO CONS. BREVETTUALE S.R.L.

REF Corresponds to:

Ref document number: 3466689

Country of ref document: DE

Date of ref document: 19871112

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
ITTA It: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 84100827.9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19990107

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19990128

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19990131

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19990201

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19990210

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19990324

Year of fee payment: 16

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000131

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000131

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000131

BERE Be: lapsed

Owner name: HOKURIKU PHARMACEUTICAL CO. LTD

Effective date: 20000131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000801

EUG Se: european patent has lapsed

Ref document number: 84100827.9

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20000126

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20000801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20001101